Skip to main content

14-08-2018 | Gout | Article

Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout

Terkeltaub R et al. Rheumatology (Oxford) 2018: key245. doi: 10.1093/rheumatology/key245

Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.

Related topics

Repurposing rheumatology drugs for COVID-19

Experts discuss the rationale, data on different agents, and the potential impact on rheumatology practice.

  • » Featuring insights from the COVID-19 Global Rheumatology Alliance, EULAR, and the Lupus Foundation of America
Image Credits